Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Yufeng Wang China

一家源于China的处于临床阶段的生物技术公司，聚焦于研发自身免疫疾病领域的创新药，为China和全世界患者提供未满足的临床用药。

Website:
www.reistonebio.com
Company Size (Fulltime employees)
51-200
Partnering Objectives
Please specify your partnering goal
License in/out
Headquartner in China
Yes
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Yufeng Wang
Reistone Biopharma
Senior Director BD 

Mei Wang China

biotech focusing on world leading r&d to solve unmet medical needs
Website:
www.dizalpharma.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
dizal pharmaceutical
team leader 

Cynthia Wang China

.
Website:
www.Servier.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Assets based licensing in
Headquartner in China
No
Servier
BD&Licensing Director 

Dr. Duan Wang China

Hengrui is the largest pharmaceutical company based in China by market cap (around 90 billion USD) and among the top ones by revenue and R&D spending (3.28b USD and 549m USD in 2019, respectively). 5+ differentiated products in global clinical development with commercial rights available for discussions.
Website:
http://www.hrs.com.cn/
Company Size (Fulltime employees)
5000+
Partnering Objectives
Please specify your partnering goal
Looking for Assets to in license and global partners
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
SHR-1701|SHR-1701is an anti-PD-L1/TGF-βRII bi-functional fusion protein that inhibits PD-L1 andTGF-β. It is currently under phase II and phase I clinical development in China and Australia, respectively. Preliminary data from SHR-1701’s two phase I trials showed promising efficacy and safety.|Solid tumor|
Assets Information 2
Pyrotinib|Pyrotinib is a novel selective tyrosine kinase inhibitor of EGFR/HER2/HER4, with superior efficacy vs. lapatinib. Global registrational trial ongoing; approved in China.|HER2-positive breast cancer|
Assets Information 3
Fluzoparib|Fluzoparib is a PARP inhibitor to address ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and other advanced solid tumors.|Solid tumor|
Biotech/Pharma Asset Stage
Jiangsu Hengrui Pharma
Associate Director of BD 
Functionality
Business Development

Renfei WANG United States

Website:
www.huyabio.com
Partnering Objectives
Please specify your partnering goal
To find new projects of interest
Headquartner in China
No
Biotech/Pharma Category
HUYA BIOSCIENCE INTERNATIONAL
Scientific liaison manager 

grace wang China

DENTAL MATERIALS
STENTS
EPIDEMIC PREVENTION PRODUCTS ETC.
Website:
www.atmbio.com
Partnering Objectives
Headquartner in China
Yes
Beijing ATMbiomaterials Co., Ltd
MD 

Dr. Zongxing Wang United States

VC in Chicago
Website:
https://www.archventure.com/
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
just check out
Headquartner in China
No
ARCH Venture Partners
Investor 

Dr Yinxiang Wang China

Website:
www.jacobiopharma.com
Company Size (Fulltime employees)
51-200
Year of foundation
5
Biotech/Pharma Category
Jacobio Pharmaceuticals
Chairman and CEO 
Functionality
Management

Ying Wang China

Pharma and diagnostics
Website:
Roche.com
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Roche
BD director 

Dr. Hong Wang United States

Pharmaceutical company
Website:
www.luye.com
Company Size (Fulltime employees)
5000+
Partnering Objectives
Please specify your partnering goal
License in
Headquartner in China
Yes
Biotech/Pharma Asset Stage
Medtech Development Stage
Luye
Senior investigator 
Functionality
Research and Development